Stock listing

LSE:0RDB Oryzon Genomics SA Share Price

UK listing (LSE) of Oryzon Genomics SA · home listing BME:ORY

Follow Oryzon Genomics SA into a list and get an email when it puts out news.

Share price · LSE:0RDB

€2.51 EUR +0.01 (+0.3%)

Close on Oct 27, 2026

Day range
€2.51 – €2.53 EUROct 27, 2026
Volume
4,491 sharesOct 27, 2026
Market cap
€101.8M EURAt the close on Oct 27, 2026 · price × 40.59M shares outstanding
Oryzon Genomics SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
BME:ORY · Home€2.428 EUR-0.07 (-2.8%)178,481€2.49€2.506€2.404€2.498Close on Oct 30, 2026
LSE:0RDB€2.508 EUR+0.008 (+0.3%)4,491€2.526€2.53€2.508€2.50Close on Oct 27, 2026
Frankfurt:ORN€2.436 EUR-0.008 (-0.3%)—€2.436€2.436€2.436€2.444Close on Oct 30, 2026
Stuttgart:ORN€2.484 EUR+0.01 (+0.4%)—€2.478€2.518€2.472€2.474Close on Oct 27, 2026
Ticker
LSE:0RDB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
EUR

What changed lately

Latest news

Oryzon Genomics S A to participate in upcoming events in November

Oct 28, 2026

Oryzon Genomics S A further strengthens vafidemstat’s patent portfolio with new decisions to grant

Oct 15, 2026

ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid Syndrome

Sep 29, 2026

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

Sep 28, 2026

ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib

Aug 31, 2026

Oryzon Genomics S A reports financial results and corporate update for half year ended June 30th, 2026

Jul 27, 2026

ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)

Jul 8, 2026

ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs

Jul 1, 2026

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

Jun 11, 2026

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Jun 2, 2026

All Oryzon Genomics SA news

Financings

  • Shares (capital increase)

    Jul 27, 2026 · US$13.65M

    Closed: €12M raised

    Use of proceeds: To support the pipeline through the clinical catalysts expected this year and beyond

    Closed Jul 27, 2026

  • Strategic investment of newly issued Oryzon shares

    Jul 27, 2026 · US$28.44M

    Update: €25M

    Buyers: Social Impact Fund (committed, as an anchor investor, to subscribe for newly issued shares for an aggregate investment of €25 million)

    Use of proceeds: To support Oryzon's mental health programs

    Update Jul 27, 2026

Read by 6ix AI from the company's releases

Decks

Oryzon Genomics SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
32 in the last 12 months · 171 in all · newest Oct 28, 2026 · oldest 2015
Decks
18 decks · latest March 2026

Where Oryzon Genomics SA is listed

ListingExchangeCountryCurrency
BME:ORY · Home listingMadridSpainEUR
gettex:ORNgettexGermanyEUR
LS Exchange:A2ACV2LS ExchangeGermanyEUR
LSE:0RDB · This pageLSEUnited KingdomEUR
OTC:ORYZFOTCUnited StatesUSD
Lang & Schwarz:A2ACV2Lang & SchwarzGermanyEUR
Aquis:ORYEAquisUnited KingdomEUR
BMV:ORYNBMVMexicoMXN
Tradegate:ORNTradegateGermanyEUR
Aquis:ORYEAquisUnited KingdomEUR
BIVA:ORYNBIVAMexicoMXN
Dusseldorf:ORNDusseldorfGermanyEUR
Frankfurt:ORNFrankfurtGermanyEUR
Hamburg:ORNHamburgGermanyEUR
Munich:ORNMunichGermanyEUR
Stuttgart:ORNStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Oryzon Genomics SA.